The label expansion sought by GSK is a bid to compete with Pfizer and Moderna in the younger age groups of the RSV vaccine market. Pfizer’s Abrysvo and Moderna’s mRESVIA are both approved to prevent ...

Recently, GSK announced that the European Medicines Agency accepted its regulatory application to expand the use of its RSV vaccine, Arexvy, to adults aged 18 and older.

FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the ...

British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...

Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine segment. See why the stock is a Buy.

Since September 2023, GSK's RSV vaccine has been approved in Japan for adults aged 60 and over. The regulatory expansion was supported by results from a global phase III trial.

RSV vaccine sales from GSK and Pfizer have dropped significantly following revised CDC guidelines, narrowing the eligible age group and reducing demand by two-thirds compared to last year.

New data for AREXVY, GSK’s RSV vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease ...

The vaccine proved a cumulative efficacy of 62.9% against respiratory syncytial virus (RSV)-related lower respiratory tract disease in older adults over 3 seasons.

Recently, GSK (LSE:GSK) announced that the European Medicines Agency accepted its regulatory application to expand the use of its RSV vaccine, Arexvy, to adults aged 18 and older. This announcement ...